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ABSTRACT
New models of data governance for health data are 
a focus of growing interest in an era of challenge to 
the social licence. In this article, we reflect on what 
the data trust model, which is founded on principles of 
participatory governance, can learn from experiences 
of involving and engagement of members of the public 
and participants in the governance of large- scale 
biobanks. We distinguish between upstream and ongoing 
governance models, showing how they require careful 
design and operation if they are to deliver on aspirations 
for deliberation and participation. Drawing on this 
learning, we identify a set of considerations important to 
future design for data trusts as they seek to ensure just, 
proportionate and fair governance. These considerations 
relate to the timing of involvement of participants, 
patterns of inclusion and exclusion, and responsiveness 
to stakeholder involvement and engagement. We 
emphasise that the evolution of governance models for 
data should be matched by a commitment to evaluation.
INTRODUCTION
Health research increasingly depends on large- scale 
data that are either purposefully collected (as in 
epidemiological studies and infrastructures) or are 
generated from routine electronic health records.1 
How to design optimal governance for use of such 
data resources is a question of increasing relevance 
in an era of rapid technological innovation and 
concerns about data privacy, surveillance and public 
trust.2 3 Finding an optimal model of governance 
for large- scale collections of health data for research 
purposes is, however, fraught with challenge.
One challenge is that of designing an approach 
up front that can endure through data collection 
and analysis over a prolonged period during which 
the available technologies and prevailing social 
conditions, law, and norms and expectations may 
undergo significant change in ways that cannot be 
anticipated.4 A further challenge is that of balancing 
the potentially divergent goals, interests and rights 
of the multiple stakeholders, including (but not only) 
those ‘data donors’ who make personal data about 
themselves available for research, as well as those 
who are concerned with the scientific value and 
outputs of large- scale data endeavours.5–8 An often 
underacknowledged challenge is that of ensuring 
that governance should be proportionate: it must 
seek to find ways of recognising and balancing both 
the risks associated with data use and the counter-
factual harms associated with non- use of health data 
that might otherwise produce collective benefits.9 10
A further challenge for governance is its role in 
securing the trustworthiness of research endeav-
ours, while being transparent about both its 
operation and limits.8 11 In this context, while indi-
vidual consent remains an important element of 
governance for health data, it is not, on its own, 
capable of providing a comprehensive solution to 
the multiple and potentially competing goals of 
governance and the other tensions that may arise 
in relation to data use.12–14 Given these complexi-
ties, tensions and fragilities, attention has turned to 
a range of new governance models. A major aim of 
these models is to secure the broader ‘social licence’ 
for data use, which experience in the area of  care. 
d ata (an English initiative designed to extract data 
from primary care medical records for purposes 
including research), for example, has shown to 
be precarious and requiring of purposeful design 
and stewardship.15 The concept of a social licence 
describes how the expectations of society regarding 
some activities may go beyond compliance with 
the requirements of formal regulation. Failure to 
fulfil the conditions for the social licence (even if 
formally compliant) may result in ongoing chal-
lenge and contestation.15
New governance models for data include, but are 
not limited to, health information commons, data 
cooperatives and data trusts.16–18 In this article, 
we propose that much can be learnt for the design 
and operation of these newer models for governing 
data from the history of governance in the area of 
biobanking. Large- scale data resources share many 
similarities with biobanks19: though they both come 
in many forms, both are premised on the collection 
of large- scale, persistent data about individuals and 
their health, and both have sought to innovate with 
participatory forms of governance. We focus our 
discussion on the data trust model,20–22 which has 
become increasingly prominent in discussion about 
data governance for research. We begin by briefly 
outlining the model, highlighting the particular 
emphasis given to the importance of participation. 
We then consider how the literature on partici-
patory governance for biobanking might usefully 
inform debates about data trusts.
DATA TRUST MODEL
Many new governance models seek to respond to 
the emerging challenges and vulnerabilities posed 
by rapid evolution in data technologies that extend 
(and often reimagine) what can be done with data, 
the appetite for data from different stakeholders, 
the twin problems of misuse and underuse of data, 
and the need to secure trustworthiness. These 
models may seek closer control over data with the 
aim of protecting the interests of individuals and 
groups while also enabling wider availability of data 
to facilitate the interests of research.23 Integral to 
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proposals for such governance models is the introduction of 
mechanisms whereby individual data donors or groups can exer-
cise the rights granted to them under law to exert control over 
the sharing and use of data (including data generated through 
analysis of biological samples) without placing restrictions on 
data that prevent its use entirely.18
In 2017, the UK government report, Growing the Artificial 
Intelligence Industry in the UK, presented the concept of ‘data 
trusts’ as institutions that might support sharing data in the 
pursuit of the public interest.21 The basic principle underlying 
the model is that there should be an independent structure for 
stewardship of data that can enable flexible and inclusive data 
governance and respect multiple interests.21 22 Data trusts are 
intended to act as independent and sustainable stewards of data 
focused on sharing data in a fair, safe and equitable way.21 They 
seek to provide inclusive, anticipatory governance of data and 
make trustworthy decisions about who has access to data, under 
what conditions, and for whose benefit.22 The data trust model 
can readily be recognised as an example of participatory gover-
nance, which is characterised by practices of public engagement 
through deliberative processes.24
Several variants of the data trust have now appeared, but they 
share many common features. Typically, a data trust involves 
a set of data resources that a trustee (more typically, a group 
of trustees) is required to managed for the benefit of other 
people (the beneficiaries) or for some other purpose than their 
own.20 25 26 Trustees, who may be drawn from a range of back-
grounds, take on a stewardship role and are responsible for 
determining how data should be used.20 25 27 Data donors or 
data subjects—those who put data into a trust and to whom data 
pertain—may be conceptualised as settlors. Settlors may them-
selves be beneficiaries of the trust,20 perhaps along with others 
(such as those seeking to use the data for research purposes).25 A 
trust charter should address its purpose and terms.22 This might 
include matters such as the trust’s guiding ethical principles and 
the duties of trustees, identification of the beneficiaries and their 
rights, the rights of settlors, how withdrawal from the trust is 
managed, and whether trustees can process or share settlors’ 
data outside the trust.25
The data trust model is not one thing, nor is it a single, rigid 
structure. For instance, in the UK, some envisage data trusts as 
operating within the legal framework of English trust law,20 with 
data trusts creating a legal relationship that gives rise to partic-
ular obligations owed by data trustees to data subjects (as bene-
ficiaries), known as fiduciary duties. Others have explored how 
different areas of law (eg, contract, commercial or charity law) 
might facilitate the aims of a data trust model27 or tended instead 
to ‘take inspiration’ from the model of beneficiaries, settlors 
and trustees (as elaborated previously) in order to formulate a 
code of governance that may establish a trust’s social licence to 
operate.25–27 Further, a multiplicity of data trusts might exist, 
allowing data subjects to select the one that most closely aligns 
with their own goals.20 In this article, we do not further consider 
the contested legal status of data trusts, which is beyond the 
scope of our discussion.27
Whatever form they take, data trusts are intended to have a 
clear purpose, a legal structure and constitution, trustees and 
beneficiaries, (some) rights and duties over stewarded data, 
arrangements for sharing benefits, and sustainable sources of 
funding and defined decision- making processes.22 Delacroix and 
Lawrence suggest that trusts may further mediate public debate 
about the relationship between individual benefits and the 
‘greater good’.20 An especially distinctive characteristic of the 
data trust model, consistent with the principles of participatory 
governance, is its emphasis on open and accountable engage-
ment with stakeholders and, in particular, with the people from 
whom data are collected or to whom it pertains.20 28 29 Hence, 
a UK review of legal and governance considerations related to 
data trusts highlights the potential for data subjects to be repre-
sented as stakeholders in the central governance of a data trust 
or in an advisory committee.27 Exactly what forms engagement, 
participation and deliberation might take in the context of data 
trusts, and how to ensure such representation is fair, remains an 
open question.
It is evident already from early pilot studies and analyses 
that little about the data trust model is likely to be straightfor-
ward.26 27 We propose that its development is likely to benefit 
from learning from other areas that have addressed some of 
the same questions, including, in particular, earlier attempts 
to address similar challenges in the area of biobanking.30 
Biobanking has been similarly characterised by calls to enable 
people to participate in deliberations on how their contributions 
can be respected and can contribute to debates about wider soci-
etal implications,5 8 16 31 but has also experienced challenges in 
operationalising and achieving these goals.
LEARNING FROM STUDIES OF INVOLVING AND ENGAGING 
PARTICIPANTS AND THE PUBLIC IN BIOBANKING
In what follows, we provide examples drawn from sources in 
the scientific literature, study websites and documentation and 
other published materials about participatory governance for 
biobanks, primarily focused on the UK and North America. Our 
aim was not to provide a systematic review of these practices, 
not least because many are sparsely reported in the scientific and 
grey literature,19 and we did not use formal searches. Instead, we 
take an authorial approach,32 drawing broadly on the literature 
and examples from our own interactions with data governance 
in the life sciences. We describe initiatives where members of the 
public and research participants are actively engaged in decision 
making about the use of data and samples in relatively planned 
ways, though we recognise that ad hoc consultations may also 
occur. We examine upstream and ongoing forms of involvement, 
distinguishing in the latter case between the involvement of indi-
viduals or groups, and between community groups and those 
directly involved in research. We reflect on the implications of 
each approach for the data trust model, including whether and 
how they have engaged with tensions around the representation 
of participants and the wider public.
Upstream consultations
The defining feature of upstream consultations is that they are 
conducted when biobank programmes are being planned and 
established, and are typically motivated by efforts to establish 
legitimacy and public trust.31 Ahead of the establishment of UK 
Biobank in the mid- 2000s, for example, Tutton et al31 argued 
for the inclusion of representatives of participants in manage-
ment bodies to foster public trust in the initiative. In practice, 
upstream engagement in UK Biobank took the form of public 
consultations on various aspects of the project, including the 
consent procedure and the ethics and governance framework. 
These consultations were criticised for failing to open up the 
core assumptions behind the project or enable members of the 
public to set the agenda for discussion.33
A subsequent wave of biobank engagements have adopted 
more deliberative approaches, seeking to provide a shared discur-
sive space for public and experts, and have been used widely.34–37 
Such approaches aim to involve the public in the discussions and 
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resolution of ethical and policy questions, typically by estab-
lishing a process and framework within which participants can 
consider diverse points of view and formulate mutually accept-
able solutions or articulate persistent disagreements.38 A detailed 
account of a deliberative approach in practice is provided by the 
British Columbia Biobank Deliberation (BCBD).38 39 The BCBD 
took place over 2 weekends and involved 25 participants who 
received information and talks from experts, asked questions 
and discussed in groups. They were given the task of coming up 
with design recommendations for a biobank. Facilitators were 
instructed to tease out disagreements and encouraged partici-
pants to elaborate on their views.38 The groups reached strong 
consensus around the value of a biobank and the need for it to 
have a governing body independent of funders and researchers, 
although there was more diversity of views on who should sit 
on this it. This finding is consistent with the other deliberative 
exercises that have emphasised the need for long- term commu-
nity oversight to promote trust and to ensure congruence with 
community values and interests.36 37 39
For data trusts, experiences in the field of biobanking suggest 
that upstream deliberative approaches may be of value in estab-
lishing, through stakeholders, the terms and values for a health 
data trust at the outset. This work may, for example, inform the 
trust charter, prior to the existence of a defined group of data 
settlors. The learning from previous work on biobanks, however, 
also makes it clear that it is important to consider who should 
be included at this stage—particularly in a context where people 
may have roles as patients, citizens consumers or advocates—
and how this may influence discussions and outcomes.39 40
Ongoing involvement
Ongoing involvement may take a number of forms. Here, we 
consider participant membership of committees and public and 
participant panels.
Participant membership of data access or ethics and governance 
committees: a shared decision-making approach
An important mode of governance in biobanks (and other large 
research studies) is that of an ethics and governance or data 
access committee. Operating at the level of individual projects 
or across networks of major bioscience initiatives—for example, 
the National Institutes of Health’s database of Genotypes and 
Phenotypes and the European Genome- Phenome Archive—
access committees aim to ensure fair, efficient, and transparent 
access to data and samples, while respecting the preferences 
and values of participants. They may draw on a wide range of 
expertise and perspectives. For example, the Access Committee 
of Generation Scotland (GSAC), a large population biobank, 
includes representation from NHS Research and Develop-
ment Offices, University Technology Transfer Offices, clinical 
academics, ethicists and experts in laboratory and data science.33 
In addition to requests for data access, GSAC discusses issues 
relating to the welfare of participants, the burden placed on 
participants by recontact and whether requests for new data may 
make participants question their health status.
In biobanking, many, if not most, access committees remain 
expert- led, even where representation from patients and the 
public is included. A distinctive approach is that of the UK’s 
Managing Ethico- social, Technical and Administrative issues in 
Data Access (METADAC) initiative. METADAC is an indepen-
dent and interdisciplinary panel that makes decisions on data and 
sample access across eight longitudinal studies.41 42 The panel 
foregrounds the importance of participant- centred decision- 
making in data access decisions, assessing the extent to which 
proposed uses of data are commensurate with participants’ 
expectations and whether the confidence of participants might 
be put at risk. Although the majority of METADAC members, 
including the chair, are experts in law, epidemiology, bioethics 
or sociology, the panel does include representation from people 
actively involved in studies as participants. At least one of two 
‘study- facing members’ must be present for the committee to be 
quorate. These members bring a participant’s perspective to data 
access decisions, although they are not participants in the studies 
for which METADAC provides oversight.
The METADAC approach provides a potentially useful model 
for data trusts. Its combination of researcher and participant 
views in decision- making would provide a means of involving 
the settlors of a data trust in key decision- making processes, 
an important consideration in maximising the value of data. 
However, as such efforts expand, clear criteria are needed for the 
selection of participants and their role in decision- making. The 
risk otherwise is that settlor involvement in data access commit-
tees may become a tokenistic quick fix that neither enables 
genuine deliberation nor facilitates genuine involvement.
Public and participant panels: a consultation and advice approach
Constitution of an independent advisory board within study 
governance arrangements is an increasingly recommended 
approach to securing involvement and engagement. One inter-
esting example is that of the Michigan BioTrust, established by 
the Michigan Department of Community Health (MDCH) to 
manage a large repository of dried blood spots from neonates 
held by the state.43 While primarily focused on the governance of 
samples, the MBT is one of few published accounts of the imple-
mentation of a charitable trust- based model of biobank gover-
nance along the lines proposed by Winickoff and Winickoff.30 
Discussing UK Biobank, Winickoff and Winickoff argued that 
a charitable trust would allow the management of the obliga-
tions of researchers related to both donated samples and the 
data derived from them while supporting research in the public 
interest.30 Winickoff subsequently proposed an overall struc-
ture for the operation of a biotrust, involving relations between 
settlors (or donors), beneficiaries and a BioTrust Foundation that 
would act as the trustee, advised by both an ethics committee 
and a donor advisory committee.44
In the case of the Michigan BioTrust, Chrysler et al43 report 
that the MDCH was considered to have fiduciary responsibili-
ties to ensure the use of the finite blood spot resource for the 
benefit of public health, extending to the population from whom 
blood spots were collected. A management group determines 
whether any proposed research is a good use of blood samples, 
guided by a tripartite arrangement of a scientific advisory board, 
an ethics committee and a community values advisory board 
(CVAB). This latter represents Michigan citizens and includes 
representatives from a range of patients’ organisations and civil 
society groups, as well as genetic counsellors and hospital asso-
ciations. The purpose of the CVAB, which meets twice a year, is 
to provide advisory input on the use of samples in research and 
the governance policies and structure of the BioTrust, and to 
inform wider community engagement and education strategies. 
This group and its reports feed into the decision- making process 
of the MDCH.45 However, little detail has been reported on the 
outcomes or effectiveness of the CVAB involvement.
The governance of the Mayo Clinic biobank similarly 
includes a citizen‐led Community Advisory Board, constituted 
of 20 members chosen to reflect the diversity of community 
interests and backgrounds.12 37 46 Its recommendations are 
not binding, but they are often incorporated into policies and 
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decisions. The board is cochaired by a member of the Mayo 
Clinic Biomedical Ethics Programme and a community member 
who is elected by CAB members. Both cochairs are also active 
voting members of the Biobank’s Biospecimen Trust Oversight 
Group and Biobank Access Committee. The board has contrib-
uted to shaping biobank policy on topics such as incidental 
research findings and practices for engagement with potential 
research participants.12
Community advisory boards of the type developed at Mich-
igan and Mayo provide a means of incorporating interested 
public and community groups in the governance of large- scale 
public bioresources. However, the perspectives they include 
do not necessarily include those of those who, in a data trust 
model, might be considered the biobanks’ ‘settlors’—partici-
pants themselves. In other studies, ‘participant panels’ have been 
established to facilitate such direct participant involvement. 
For example, the governance of the Avon Longitudinal Study 
of Parents and Children cohort includes an independent ethics 
and law Committee (ALEC).47 This committee comprises clini-
cians, researchers, people with legal expertise and lay people, 
including study participants. At least two study participants must 
be present for the group to be quorate. Further, the decisions of 
the ALEC are made alongside those of a committee of research 
participants (and, since 2006, a ‘teenage advisory panel’, estab-
lished when the child participants were 15 years old). This 
committee of 30 cohort participants meets every two months to 
comment on study design, methodology and acceptability for 
participants.47
Various other participant panels or ‘patient forums’ have 
recently been described.48 49 The 100,000 Genomes Project, for 
example, incorporates a panel of 30 participants meeting three 
times a year. Its members sit on the data access review committee, 
the ethics advisory committee and the board of the Genomics 
England Clinical Interpretation Partnership.50 Similarly, the US 
All of Us Precision Medicine Initiative has made a significant 
commitment to ‘highly interactive participation’, which aims to 
transform ‘patients into partners’.51 It currently involves a group 
of 32 participant representatives, 8 of whom sit on the study 
advisory panel, steering committee and executive committee.52
For data trusts, an advice and consultation role for participants 
through specially constituted groups or panels may be valuable, 
providing for representation and protection of the interests of 
people who have a clear stake in decision making about data use. 
However, it is important that the roles and responsibilities of 
such groups and panels are clearly articulated, that their impact 
on decision- making is transparent, and that the time and finan-
cial costs associated with involving participant groups in deci-
sion making are proportionate with need for input into decision 
making.
The distinction between participant groups and community 
groups may be especially important to data trust governance: 
participants are better able to speak to the risks associated with 
uses of data provided by them, but also have an interest in 
the uses of data that may not necessarily align with a ‘public’ 
interest. Similarly, in the case of a data trust, trustees must 
manage data in the interests of participants but also consider 
whether broader engagement may be justified on some issues of 
societal concern. Balancing these interests will depend to some 
extent not only on the matter at issue but also on the purpose 
of the data trust as set out in the trust charter, and the expecta-
tions of stakeholders this charter represents—not only of data 
subjects, but also potentially of both public and private sector 
groups.
DISCUSSION
As the capacity to collect data from diverse sources and use them 
to study and make decisions about health and healthcare grows, 
it is important that data governance evolves as well. Increasing 
consensus is emerging that decisions about collecting, sharing 
and using data should incorporate the perspectives of all stake-
holders, including and especially those who provide data.13 A 
system of independent data trusts with differing goals, estab-
lished according to charters drawn up in consultation with stake-
holders to represent their aspirations for data use, may be one 
architecture for achieving the multiple goals of governance.20 In 
this article, we have shown that learning from experiences in the 
area of biobanking in the UK and North America offers insights 
into some of the complexities and challenges in participatory 
governance for data trusts (box 1). It makes clear that an aspi-
ration to include diverse interests, including those of patients, 
participants and the public, in governance does not in of itself 
ensure fair decisions. Data trusts and the principles of participa-
tory governance that inform them are not inherently just53: they 
require careful design and operationalisation.
The learning from governance of biobanks highlights several 
important considerations that are essential to ensure the future 
development of governance practices for data trusts is fair, effec-
tive and proportionate. They relate to the timing of involve-
ment of participants, patterns of inclusion and exclusion, and 
responsiveness to stakeholder involvement and engagement, and 
capturing the impact of such activities on decisions about data 
through evaluation. As the plurality of data trusts among which 
data subjects can choose to settle their data grows—from those 
that place a heavy emphasis on societal benefits to those that 
prioritise commercial gains—systematic consideration of these 
considerations will grow in significance.20
With regard to timing, the experiences described previously 
emphasise that both ‘upstream’ and ‘ongoing’ forms of involve-
ment and engagement have potential value. Prospective delib-
eration anchors governance in the values and aspirations of the 
wider population who are expected to support research. As 
such, it can both contribute to defining what constitutes societal 
value and establish the trustworthiness of initiatives, providing 
the basis for a social licence, and will be critical to setting the 
overall goals, terms and tone of a data trust. Ongoing involve-
ment of participants enables constant reflection and adapta-
tion in response to the experiences of the people most directly 
affected by research decisions. Data trusts are likely to benefit 
from both well- designed upstream and ongoing involvement and 
engagement. Where data trusts either draw on population data 
or target population- level impacts, but disproportionately rely 
on data from a smaller group of participants, finding the right 
balance between upstream and ongoing engagement will be key.
Box 1 Recommendations
 ► The legitimacy of data trusts relies on open and accountable 
engagement with stakeholders. These may include both data 
subjects and the wider public.
 ► If multiple data trusts exist, the appropriate form of 
participatory governance will differ, depending on the terms 
of the trust charter.
 ► Careful consideration must be given to who is involved, why 
they are involved, at what stage and for what purpose.
 ► The data trust model is still evolving and would benefit from 
rigorous evaluation.
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A recognition of the uneven distribution of the benefits and 
burdens of health research, and the heterogeneity of perspec-
tives, positions and interests that underpin the social licence 
demands careful design and transparency about who is included 
in governance and how they come to be included. Biobanking 
approaches are sometimes criticised for their potential to priv-
ilege the perspectives of those involved in research over a civic 
voice or the rights and interests of minority or excluded groups.54 
This is particularly challenging for involvement models that focus 
on individuals or small groups, which may favour those who are 
well connected, better informed or have performed such roles 
in the past.55 The broader movement to promote patient and 
public involvement and engagement in health has raised similar 
concerns.56 For example, when critical perspectives have inter-
rogated this movement, they have drawn attention to the need 
for attention to who is involved and their interests, who gets 
to speak on behalf of whom, distinctions between patients and 
the public, and the existence of multiple publics.56–58 These are 
important questions for data trusts. Consistent with principles of 
fairness and justice, careful and transparent consideration should 
be given to how decisions about inclusion and representation 
are reached and with what consequences for those who may be 
at risk of being underserved, excluded or marginalised; whose 
voices get heard and with what responses; and whose interests 
are ultimately served. The role of trustees and the ways in which 
they make decisions will require careful scrutiny in this regard.
This article has sought to offer learning from the field of 
biobanking that will be helpful in identifying relevant consid-
erations for participatory governance for data trusts both in the 
UK and globally. It has some limitations; we did not conduct a 
systematic search of the literature nor did we engage in formal 
critical appraisal of individual reports and studies. A striking 
finding of our work, however, is that the enthusiasm for partic-
ipatory governance for health research has not been matched 
by a commitment to rigorous evaluation, meaning that learning 
from previous efforts (including in the area of biobanking) has 
not been maximised. What is clear is that relying on participa-
tory governance both as a way of ensuring justice and fairness, 
and as a way of securing legitimacy or the social licence for data 
use for research, requires careful design and operationalisation, 
together with explicit recognition that expectations and aspira-
tions related to data use are diverse and multiple, not a uniform 
social whole.59 Showing how those entrusted with data act in 
response to the input of stakeholders and in relation to their 
values is essential to building trust and confidence in data trusts, 
meaning that evaluation must be centre stage.
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